Smith & NephewSNN +5.29%84 Return-on-Tangible-Equity is 48.08% as of Dec. 2025, which is 9% below its 10-year median of 52.55. GuruFocus rates SNN with a GF Score™ of 84/100 and a GF Value™ of $31.58 (Fairly Valued). The stock has 3 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Smith & Nephew ranks better than 91.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Smith & Nephew's annualized net income for the quarter that ended in Dec. 2025 was $664 Mil. Smith & Nephew's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $1,381 Mil. Therefore, Smith & Nephew's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 48.08%.
The historical rank and industry rank for Smith & Nephew's Return-on-Tangible-Equity or its related term are showing as below:
SNN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 21.51 Med: 52.55 Max: 213.06
Current: 46.34
During the past 13 years, Smith & Nephew's highest Return-on-Tangible-Equity was 213.06%. The lowest was 21.51%. And the median was 52.55%.
SNN's Return-on-Tangible-Equity is ranked better than 91.83% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs SNN: 46.34
Smith & Nephew (NYSE:SNN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Smith & Nephew Return-on-Tangible-Equity Related Terms
Smith & Nephew Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNN vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Smith & Nephew's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 48.08% mean?
Smith & Nephew (SNN) has a Return-on-Tangible-Equity of 48.08% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Smith & Nephew and its competitors. This is near median its historical median of 52.55. Over the past decade, Smith & Nephew's Return-on-Tangible-Equity has ranged from 21.51 to 213.06. According to the industry distribution chart, Smith & Nephew ranks #62 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 8.2%.
Is Smith & Nephew's Return-on-Tangible-Equity too high?
Smith & Nephew's current Return-on-Tangible-Equity of 48.08% is near median its 10-year median of 52.55. Over the past 10 years, this metric has ranged from a low of 21.51 to a high of 213.06. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. Smith & Nephew's value of 48.08% is 1081.3% above this industry median. Based on the distribution chart, Smith & Nephew ranks #62 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Smith & Nephew has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #62 out of 759 companies for Return-on-Tangible-Equity. This places Smith & Nephew in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.07. Smith & Nephew's value of 48.08% is 1081.3% above this benchmark. Historically, Smith & Nephew's own Return-on-Tangible-Equity has ranged from 21.51 to 213.06 over the past decade. While the company's 10-year median is 52.55 vs. the industry median of 4.07, Smith & Nephew has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current Return-on-Tangible-Equity of 48.08% is 1081.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current Return-on-Tangible-Equity is 48.08%, which is near median its own 10-year median of 52.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (SNN) is currently considered Fairly Valued. The stock's GF Value™ is $31.58, compared to a current price of $30.25 — trading 4.2% below its estimated fair value. The current Return-on-Tangible-Equity is 48.08%, which is near median its 10-year median of 52.55 and 1081.3% above the Medical Devices & Instruments industry median of 4.07. Smith & Nephew's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Smith & Nephew (SNN), the current Return-on-Tangible-Equity is 48.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (SNN) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of $30.25 is trading 4.2% below its estimated GF Value™ of $31.58.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for SNN:
Return-on-Tangible-Equity: 48.08% (near median its 10-year median of 52.55)
GF Value™: $31.58 vs. price of $30.25 (4.2% below fair value)
Industry Position: 1081.3% above the Medical Devices & Instruments median (#62 of 759)
No single metric tells the full story. See the SNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
84GF Score
Get the complete analysis for SNN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNN has been successfully added to your 
